紫杉醇脂质体治疗非小细胞肺癌40例近期疗效及安全性分析

目的比较国产紫杉醇脂质体与紫杉醇联合顺铂治疗非小细胞肺癌的疗效和安全性。方法病理诊断明确的晚期非小细胞肺癌患者随机进入试验组和对照组。试验组每周期予以紫杉醇脂质体135 mg/m2，对照组每周期予以紫杉醇135 mg/m2。两组每周期均联合顺铂75 mg/m2，每三周为一周期，两周期后评价疗效及安全性。结果82例患者进入该研究。试验组40例，对照组42例。其中81例患者可评价疗效和不良反应。试验组总有效率27.5％，对照组总有效率24.4％，两组有效率差异无统计学意义。两组血液学毒性发生率差异无统计学意义。但周围神经病变及聚氧乙基代蓖麻油与无水乙醇的混合溶媒所产生的相关毒性,试验组发生率明显低于对照组,差异有统计学意义。结论紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌疗效与紫杉醇相当，但过敏反应和周围神经病变的发生率明显降低。

Efficacy and Safety of Paclitaxel Liposomes in Treatment of 40 Patients with NSCLC

Objective To compare the efficacy and safety of domestic-made Paclitaxel liposomes with Paclitaxel in the treatment of NSCLC.Methods 82 patients with advanced NSCLC were prospectively randomized into two groups,experimental group were given Paclitaxel liposome at 135 mg/ m2 each cycle,and control group were given Paclitaxel at 135 mg/ m2.Both groups combined with DDP at 75 mg/ m2 per cycle every three weeks.The efficacy and safety were evaluated after two cycles.Results 82 patients were enrolled into this s...